NOVN logo

Novartis Community

SWX:NOVN Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 119 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

NOVN logo
Novartis
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 18 Analysts

Pluvicto And Radioligand Pipeline Will Expand Future Markets

Key Takeaways Novartis' innovative drug launches and radioligand therapy pipeline position it for significant growth and revenue diversification. Strong market penetration and sales of drugs like Kisqali, coupled with U.S. investment, support long-term net margin and EPS growth.
View narrative
CHF 98.33
FV
6.1% undervalued intrinsic discount
1.94%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
79users have followed this narrative
3 days ago author updated this narrative